for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acorda Therapeutics Inc

ACOR.O

Latest Trade

2.07USD

Change

-0.08(-3.72%)

Volume

1,658,645

Today's Range

2.06

 - 

2.18

52 Week Range

1.49

 - 

17.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Acorda Therapeutics Files For Resale Of Up To 9.6 Mln Shares Of Common Stock

Jan 15 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 9.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.

Acorda Sees Total Product Net Revenue For 2020 To Be $120 - $150 Mln

Jan 15 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA PROVIDES 2019 HIGHLIGHTS AND 2020 GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE.TOTAL PRODUCT NET REVENUE FOR FULL YEAR 2020 IS EXPECTED TO BE $120 - $150 MILLION.TOTAL REVENUE FOR 2020 IS EXPECTED TO BE $130 - $160 MILLION..EXPECTED INBRIJA U.S. ANNUAL PEAK SALES FOR 2020 HAS BEEN REVISED TO $300 - $500 MILLION.AMPYRA NET REVENUE FOR FULL YEAR 2020 IS EXPECTED TO BE $85 - $110 MILLION.FY2020 REVENUE VIEW $143.9 MILLION -- REFINITIV IBES DATA.

Canyon Capital Advisors Reported A Passive Stake Of 14% In Acorda Therapeutics Inc As Of Dec 31, 2019 - SEC Filing

Jan 13 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::CANYON CAPITAL ADVISORS LLC REPORTED A PASSIVE STAKE OF 14% IN ACORDA THERAPEUTICS INC AS OF DEC 31, 2019 - SEC FILING.

Point72 Asset Management Reports A Passive Stake Of 9.8% In Acorda Therapeutics

Jan 2 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::POINT72 ASSET MANAGEMENT, L.P. REPORTS A PASSIVE STAKE OF 9.8% IN ACORDA THERAPEUTICS INC AS OF DEC 26, 2019 - SEC FILING.

Acorda Therapeutics Reports Q3 Results

Nov 4 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::Q3 NON-GAAP LOSS PER SHARE $0.46.Q3 GAAP LOSS PER SHARE $5.55.Q3 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.FOR QUARTER ENDED SEPTEMBER 30, 2019, COMPANY REPORTED INBRIJA NET REVENUE OF $4.9 MILLION.QTRLY AMPYRA NET REVENUE OF $37.6 MILLION COMPARED TO $137.8 MILLION FOR SAME QUARTER IN 2018.AT SEPTEMBER 30, 2019, COMPANY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $253 MILLION.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $55 - $60 MILLION.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2020 ARE EXPECTED TO BE $20 - $25 MILLION.TOTAL OPERATING EXPENSES IN 2020 ARE ESTIMATED TO BE ABOUT $60 MILLION LESS THAN IN 2019.QTRLY TOTAL REVENUES $47.7 MILLION VERSUS $142.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.51, REVENUE VIEW $44.7 MILLION -- REFINITIV IBES DATA.

Acorda Therapeutics Implements Corporate Restructuring, Provides Q3 Update

Oct 23 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS IMPLEMENTS CORPORATE RESTRUCTURING, PROVIDES THIRD QUARTER 2019 UPDATE.ACORDA THERAPEUTICS INC - ESTIMATED 2020 OPERATING EXPENSES REDUCED BY ABOUT $60 MILLION COMPARED TO 2019 REVISED GUIDANCE.ACORDA THERAPEUTICS INC - TOTAL NON-GAAP OPERATING EXPENSES FOR FULL YEAR 2020 EXPECTED TO BE $180 - $190 MILLION.ACORDA THERAPEUTICS INC - INBRIJA AND AMPYRA Q3 2019 NET SALES OF ABOUT $5 MILLION AND ABOUT $38 MILLION, RESPECTIVELY.ACORDA THERAPEUTICS INC - ESTIMATES THAT IT WILL INCUR ABOUT $8 MILLION OF PRE-TAX CHARGES RELATED TO RESTRUCTURING, THROUGH Q1.ACORDA THERAPEUTICS INC - AS PART OF THIS RESTRUCTURING, ACORDA IS REDUCING HEADCOUNT BY APPROXIMATELY 25% THROUGH A REDUCTION IN FORCE.ACORDA THERAPEUTICS - EXPECTS TO REALIZE ESTIMATED ANNUALIZED COST SAVINGS RELATED TO HEADCOUNT REDUCTION OF APPROXIMATELY $21 MILLION BEGINNING IN 2020.ACORDA THERAPEUTICS INC - RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2020 ARE EXPECTED TO BE $20 - $25 MILLION.ACORDA THERAPEUTICS INC - RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $55 - $60 MILLION, REDUCED FROM $70 - $80 MILLION.

Acorda Therapeutics Says Intends To Provide Additional Inbrija Launch Updates On Q3 2019 Conference Call

Oct 4 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC - PROVIDING AN UPDATE ON MANAGED CARE ACCESS FOR INBRIJA™ (LEVODOPA INHALATION POWDER).ACORDA THERAPEUTICS INC - INTENDS TO PROVIDE ADDITIONAL INBRIJA LAUNCH UPDATES ON ITS Q3 2019 CONFERENCE CALL SCHEDULED FOR NOV 4, 2019.ACORDA THERAPEUTICS-INBRIJA IS NOW AVAILABLE IN U.S. WITHOUT NEED FOR MEDICAL EXCEPTION FOR ABOUT 66% OF COMMERCIAL, ABOUT 25% OF MEDICARE PLAN LIVES.

Acorda Therapeutics Said That EC Has Granted Marketing Authorization For Inbrija 33 Mg Inhalation Powder, Hard Capsules

Sept 24 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ON SEPT 24,CO SAID THAT EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR INBRIJA 33 MG INHALATION POWDER, HARD CAPSULES.MARKETING AUTHORIZATION APPROVES INBRIJA FOR USE IN 28 COUNTRIES OF EUROPEAN UNION, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN.

Acorda Posts Q2 Loss Per Share Of $0.58

Aug 1 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA PROVIDES UPDATE FOR SECOND QUARTER ENDED JUNE 30, 2019.Q2 NON-GAAP LOSS PER SHARE $0.55.Q2 GAAP LOSS PER SHARE $0.58.Q2 EARNINGS PER SHARE ESTIMATE $-1.06 -- REFINITIV IBES DATA.COMPANY EXPECTS AMPYRA NET REVENUE FOR FULL YEAR 2019 TO BE GREATER THAN $140 MILLION.DURING INBRIJA'S LAUNCH YEAR, COMPANY DOES NOT EXPECT TO PROVIDE INBRIJA REVENUE GUIDANCE.

Acorda Therapeutics Reports Q1 Non-GAAP Loss Per Share Of $0.56

May 2 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA PROVIDES UPDATE FOR FIRST QUARTER ENDED MARCH 31, 2019.Q1 NON-GAAP LOSS PER SHARE $0.56.Q1 GAAP LOSS PER SHARE $1.00.Q1 EARNINGS PER SHARE ESTIMATE $-0.94 -- REFINITIV IBES DATA.FOR QUARTER ENDED MARCH 31, 2019, REPORTED AMPYRA NET REVENUE OF $40.1 MILLION COMPARED TO $102.8 MILLION.EXPECTS AMPYRA REVENUE TO CONTINUE TO DECLINE.ACORDA - WILL NO LONGER PROVIDE REVENUE GUIDANCE FOR AMPYRA, DUE TO UNPREDICTABLE TRAJECTORY OF REVENUE DECLINE GIVEN ENTRANCE OF GENERICS.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $70-$80 MILLION.SG&A EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $200-$210 MILLION.ACORDA THERAPEUTICS - QTRLY TOTAL REVENUE $44.1 MILLION VERSUS $106.2 MILLION.Q1 REVENUE VIEW $33.0 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up